The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease

Brain Research

Volumn 1019, Issue 1-2, 2004, Pages 246-254

  Schiefer, Johannes ^a   Sprünken, Arne ^a   Puls, Christiane ^a   Lüesse, Hans Gerd ^a   Milkereit, Anna ^a   Milkereit, Eva ^a   Johann, Verena ^a   Kosinski, Christoph M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Degenerative disease: other; Disorders of the nervous system; Excitotoxicity; Glutamate receptor antagonist; Neurodegenerative disease; Neuroprotection; Polyglutamine disease; Therapy

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC GLUTAMATE RECEPTOR 2 AGONIST; METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOTOR COORDINATION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 4043164771     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.06.005     Document Type: Article

References (57)

1. Andreassen O.A., Ferrante R.J., Huang H.M., Dedeoglu A., Park L., Ferrante K.L., Kwon J., Borchelt D.R., Ross C.A., Gibson G.E., Beal M.F. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 50:2001;112-117
2. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1991;1649-1659
3. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 125:2002;1908-1922
4. Bond A., Jones N.M., Hicks C.A., Whiffin G.M., Ward M.A., O'Neill M.F., Kingston A.E., Monn J.A., Ornstein P.L., Schoepp D.D., Lodge D., O'Neill M.J. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. 294:2000;800-809
5. Borlongan C.V., Koutouzis T.K., Freeman T.B., Cahill D.W., Sanberg P.R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 697:1995;254-257
6. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 73:2002;359-366
7. Bruno V., Ksiazek I., Battaglia G., Lukic S., Leonhardt T., Sauer D., Gasparini F., Kuhn R., Nicoletti F., Flor P.J. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology. 39:2000;2223-2230
8. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19:1999;3248-3257
9. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15:2000;925-937
10. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23:2000;387-392
11. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U. S. A. 95(11):1998;6480-6485
12. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:2000;797-801
13. Davies S., Turmaine M., Cozens B., DiFiglia M., Sharp A., Ross C., Scherzinger E., Wanker E., Mangiarini L., Bates G. Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548
14. DiFiglia M., Sapp E., Chase K., Davies S., Bates G., Vonsattel J., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993
15. D'Onofrio M., Cuomo L., Battaglia G., Ngomba R.T., Storto M., Kingston A.E., Orzi F., De Blasi A., Di Iorio P., Nicoletti F., Bruno V. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 78:2001;435-445
16. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20:2000;4389-4397
17. File S.E., Mahal A., Mangiarini L., Bates G.P. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res. 805:1998;234-240
18. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 38:1999;1493-1503
19. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;147-157
20. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19(7):1999;2522-2534
21. Huntington G. On chorea. Med. Surg. Rep. 26:1872;317-321
22. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983
23. Hurlbert M., Zhou W., Wasmeier C., Kaddis F., Hutton J., Freed C. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes. 48:1999;649-651
24. Kim M., Lee H.S., LaForet G., McIntyre C., Martin E.J., Chang P., Kim T.W., Williams M., Reddy P.H., Tagle D., Boyce F.M., Won L., Heller A., Aronin N., DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19(3):1999;964-973
25. Kingston A.E., O'Neill M.J., Bond A., Bruno V., Battaglia G., Nicoletti F., Harris J.R., Clark B.P., Monn J.A., Lodge D., Schoepp D.D. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Ann. N.Y. Acad. Sci. 890:1999;438-449
26. Kingston A.E., O'Neill M.J., Lam A., Bales K.R., Monn J.A., Schoepp D.D. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol. 377:1999;155-165
27. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 95(1):1998;41-53
28. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:1997;160-165
29. Kosinski C., Cha J., Young A., Persichetti F., MacDonald M., Gusella J., Penney J., Standaert D. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp. Neurol. 144:1997;239-247
30. Kosinski C.M., Cha J.H., Young A.B., Mangiarini L., Bates G., Schiefer J., Schwarz M. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. NeuroReport. 10:1999;3891-3896
31. Kosinski C., Standaert D., Counihan T., Scherzer C., Kerner J., Dagget L., Velecelebi G., Penney J., Young A., Landwehrmeyer G. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J. Comp. Neurol. 390:1998;63-74
32. Koutouzis T.K., Borlongan C.V., Freeman T.B., Cahill D.W., Sanberg P.R. Intrastriatal 3-nitropropionic acid: a behavioral assessment. NeuroReport. 5:1994;2241-2245
33. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58:1999;515-532
34. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8:2001;807-821
35. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 19:1999;10428-10437
36. Lüesse H., Schiefer J., Sprünken A., Puls C., Block F., Kosinski C.M. Evaluation of R6/2 transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 126:2001;185-195
37. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S., Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506
38. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.J., Li H., Zeitlin S., Chesselet M.F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22:2002;8266-8276
39. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L. Jr., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42:1999;1027-1040
40. Nicoletti F., Bruno V., Copani A., Casabona G., Knöpfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19:1996;267-271
41. Nicoletti F., Bruno V., Catania M.V., Battaglia G., Copani A., Barbagallo G., Cena V., Sanchez-Prieto J., Spano P.F., Pizzi M. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology. 38:1999;1477-1484
42. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267
43. Pisani A., Calabresi P., Centonze D., Bernardi G. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br. J. Pharmacol. 120:1997;1007-1014
44. Pisani A., Bernardi G., Bonsi P., Centonze D., Giacomini P., Calabresi P. Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids. 19:2000;119-129
45. Popik P., Wrobel M. Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology. 43:2002;1210-1217
46. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O. Jr., Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20:1998;198-202
47. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., Cudkowicz M.E. Riluzole therapy in Huntington's disease (HD). Mov. Disord. 14:1999;326-330
48. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 421:2003;373-379
49. Saudou F., Finkbeiner S., Devys D., Greenberg M. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66
50. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 17:2002;748-757
51. Sharpe E.F., Kingston A.E., Lodge D., Monn J.A., Headley P.M. Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br. J. Pharmacol. 135:2002;1255-1262
52. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132:2001;1423-1430
53. Testa C.M., Standaert D.G., Landwehrmeyer G.B., Penney J.B. Jr., Young A.B. Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J. Comp. Neurol. 354:1995;241-252
54. Testa C.M., Friberg I.K., Weiss S.W., Standaert D.G. Immunohistochemical localization of metabotropic Glutamate Receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol. 390:1998;5-19
55. Yang W., Dunlap J.R., Andrews R.B., Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11:2002;2905-2917
56. Zeron M.M., Chen N., Moshaver A., Ting-Chun Lee A., Wellington C.L., Hayden M.R., Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17:2001;41-53
57. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33:2002;849-860